Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Overweight and raises the price target from $34 to $39.
Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Overweight and raises the price target from $34 to $39.